This meta-analysis was conducted to bridge the outlined gap by investigating the efficacy and safety of SGLT2 inhibitor therapy on clinical and cardiac remodeling outcomes in patients with AMI irrespective of HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.